Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

VG Life Sciences Inc (VRALD) USD0.0001

Sell:$0.0148 Buy:$0.0148 Change: $0.0052 (54.17%)
Market closed |  Prices as at close on 7 August 2020 | Switch to live prices |
Change: $0.0052 (54.17%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Market closed |  Prices as at close on 7 August 2020 | Switch to live prices |
Change: $0.0052 (54.17%)
Market closed |  Prices as at close on 7 August 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

VG Life Sciences Inc. is a biotechnology company. The Company is engaged in developing transformative therapies to treat drug-resistant cancers, infectious diseases and autoimmune diseases caused by chronic inflammation. The Company operates as a drug discovery and development company researching two core technologies: Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). The Company's MDT compounds impede tumor cells' ability to meet their energy requirements, leaving cancer cells vulnerable to cancer-killing agents. Its autoimmune therapy, TPT, eliminates a subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. Its peptides are designed to function in all Major Histocompatibility Complex II (MHC-II) phenotypes. It also has a drug research program in pre-clinical stages, a TPT therapy for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) using VG1177.

Contact details

PO Box 1020
United States
+1 (805) 8799000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.50 million
Shares in issue:
107.88 million
OTC Bulletin Board
United States
US dollar

Key personnel

  • Haig Keledjian
    Founder, Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Vice President - Research & Development, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.